Rituximab in Patients With Phospholipase A2 Receptor–Associated Membranous Nephropathy and Severe CKD

INTRODUCTION: Patients with phospholipase A2 receptor (PLA2R)–associated membranous nephropathy and stage 4 or 5 chronic kidney disease are at high risk of end-stage kidney disease. In recent years, rituximab (RTX) emerged as a safe and efficient treatment for patients with PLA2R-associated membrano...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanset, Nicolas, Esteve, Emmanuel, Plaisier, Emmanuelle, Johanet, Catherine, Michel, Pierre-Antoine, Boffa, Jean-Jacques, Fievet, Patrick, Mesnard, Laurent, Morelle, Johann, Ronco, Pierre, Dahan, Karine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7056852/
https://www.ncbi.nlm.nih.gov/pubmed/32154454
http://dx.doi.org/10.1016/j.ekir.2019.12.006